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Abstract
Mediators of cholera toxin (CT)-induced fluid secretion include 3P,5P-adenosine monophosphate (cAMP), prostaglandin
E2 (PGE2), and 5-hydroxytryptamine (5-HT). Administration of L-histidine significantly reduced the net secretory response
of the small intestine of mice challenged with CT and reduced the capacity of PGE2 to stimulate Na transport in Ussing
chambers. We demonstrated that L-histidine chemically modified the structure of PGE2 but had no direct effect on cAMP or
5-HT. L-Histidine and imidazole reacted with PGE2 in vitro in cell-free mixtures incubated at 37‡C and pH 7.0 under an
atmosphere of N2 with the formation of PGE2^imidazole and PGE2^histidine covalent adducts. Nuclear magnetic resonance
(NMR) spectroscopy and mass spectrometry (MS) analysis of the purified adduct showed that imidazole catalyzed the
dehydration of PGE2. A Michael adduct then was formed between C11 of 11-deoxy-v10 PGE2 (PGA2) and the tau nitrogen
in the imidazole ring of L-histidine. Importantly, the isolated PGE2^imidazole and PGE2^histidine adducts inhibited CT-
induced fluid loss and cAMP accumulation in mouse intestinal loops. The protection provided by PGE2^imidazole, PGE2^
histidine, and L-histidine against intestinal fluid loss could provide a basis for future therapy against cholera. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
In some diseases such as cholera, the formation of
eicosanoids is evoked by cholera toxin (CT) [1^3],
and prostaglandin E2 (PGE2) can regulate water
and electrolyte transport in the small intestine with-
out noticeable in£ux of leukocytes or tissue damage
[3,4]. The mechanism of CT action involves both an
increase in the intestinal level of 3P,5P-adenosine
monophosphate (cAMP) and PGE2, as well as a
role for cAMP-mediated release of 5-hydroxytrypt-
amine (5-HT) and stimulation of the enteric nervous
system [5^8]. In comparison, in£ammatory diseases
(e.g., Crohn’s disease, ulcerative colitis, and rheuma-
toid arthritis) are mediated by cellular signals from
eicosanoids and cytokines released during cell injury
or in response to foreign substances [9]. Some eico-
sanoids, such as PGE2 and leukotriene B4 (LTB4),
participate in the recruitment of polymorphonuclear
neutrophils (PMNs) and mononuclear cells [9] into
the in£amed intestinal tissue. Frequently, the acute
or chronic in£ammatory response culminates in ex-
tensive tissue damage due to release of reactive oxy-
gen species (ROS; e.g., free hydroxyl radicals and
singlet oxygen) and reactive nitrogen species (RNS).
Peterson et al. [10] reported that L-histidine protected
mouse small intestine from tissue damage upon in-
fection with Salmonella typhimurium, in a manner
similar to that seen by passive transfer of antibodies
to tumor necrosis factor-K (TNF-K) [11]. We demon-
strated that L-histidine’s anti-oxidant capacity re-
duced reactive oxygen species (ROS) formed in re-
sponse to lipopolysaccharide (LPS) in cultured
mononuclear cells in vitro [10]. L-Histidine also pro-
tected mouse intestinal mucosa from £uid loss during
infection of intestinal loops with S. typhimurium [10].
In this report, we observed that L-histidine and imi-
dazole reacted chemically with PGE2, but not with 5-
HT or cAMP, to form covalent adducts. The struc-
tures of the adducts were determined by mass spec-
trometry (MS) and nuclear magnetic resonance
(NMR) spectroscopy, and the potential medical val-
ue of the adducts was examined with a murine model
of experimental cholera.
2. Materials and methods
2.1. Reagents
CT and L-histidine (HCl) were purchased from
Sigma Chemical Co. (St. Louis, MO). The 175-mM
solution of L-histidine (pH 7.0) was freshly prepared
for injection by adjusting to 300 mosmol with NaCl
before sterilization with a 0.2-Wm ¢lter. Imidazole, 1-
methyl-L-histidine, and 3-methyl-L-histidine were
purchased from Sigma, and U-[15N]imidazole was
from Cambridge Isotope Laboratories, Andover,
MA. A phosphate-bu¡ered saline (PBS) solution
was made with 137 mM NaCl, 2.7 mM KCl, 1.2
mM Ca2Clc2H2O, 0.49 mM Mg2Clc6H2O, 8.1 mM
Na2HPO4, and 1.47 mM KH2PO4 (pH 7.4).
2.2. Mouse intestinal loop assay
Adult female Swiss^Webster mice (6^8 weeks old)
were purchased from Taconic Farms (Germantown,
NY) and housed in a speci¢c pathogen-free animal
facility at UTMB in Galveston, TX. Mice were given
water without food for 18 h before surgery to reduce
the food content of the small intestine. A ventral
midline incision was made under halothane anesthe-
sia to expose the small intestine. A single 5-cm seg-
ment of small intestine, ligated with ‘00’ silk suture,
was constructed in each mouse. After 6 h of obser-
vation, the animals were euthanized by cervical dis-
location, and the intestinal loops were removed. The
amount of luminal £uid was measured and expressed
as Wl/cm. Intestinal challenge was accomplished by
injecting CT (1 Wg) with or without 175 mM L-histi-
dine in 100 Wl of PBS, followed by intraperitoneal
injections (100 Wl) of 175 mM L-histidine at the
time of challenge and every 2 h thereafter until the
experiment was terminated at 6 h. In other experi-
ments, the dose of L-histidine was varied and admin-
istered by either the luminal or the intraperitoneal
route at the time of challenge and at various times
thereafter. Fluid accumulation and cell culture data
(next section) were analyzed by a two-tailed Stu-
dent’s t-test for independent samples or by Dunnett’s
Multiple Group Comparison test (Epistat Services.
Richardson, TX).
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2.3. Cell culture assay
The inhibitory e¡ect of L-histidine on PGE2 stim-
ulation of adenylate cyclase activity in Chinese ham-
ster ovary (CHO) cells was measured with a cAMP
ELISA. CHO cells (4U105) were plated in 35-mm
dishes in Ham’s F12 medium containing 10% fetal
bovine serum (FBS). After overnight incubation at
37‡C with 5% CO2, the attached cells were covered in
2 ml of fresh medium, with or without L-histidine
solution (4.7 mM). All cells were stimulated with
CT at indicated concentrations for 6 h.
2.4. Ion transport studies
The inhibitory e¡ect of L-histidine on PGE2-stimu-
lated sodium transport was estimated from the short-
circuit current in Ussing chambers ¢tted with Xeno-
pus laevis epidermis. PGE2 (Sigma) was diluted to a
concentration of 1 WM and incubated for 30 min
with 10 mM L-histidine before adding to the cham-
bers at 37‡C. A reduction in short-circuit current Isc
was an indication that L-histidine had altered the
biological activity of PGE2. The principal solution
used in the Ussing chamber studies was a NaCl
Ringer solution composed of 90 mM NaCl, 2.5
mM KCl, 1.0 mM MgCl2, 0.5 mM NaH2PO4, 1.8
mM CaCl2, and 10.0 mM HEPES. A tetramethylam-
monium chloride (TMA-Cl) Ringer solution was
used, in which the NaCl was replaced by 90 mM
TMA-Cl, keeping KCl, CaCl2, and HEPES at the
same concentrations as the NaCl Ringer. A 10-mM
L-histidine solution was prepared with the same com-
ponents and concentrations as the NaCl Ringer, ex-
cept the concentration of NaCl was reduced to 85
mM. The PGE2 solution was made by adding 20 Wl
of PGE2 dissolved in H2O to either the NaCl Ringer
or to the L-histidine solution to obtain the desired
concentration of 1 WM. Each of these solutions was
titrated to a pH of 7.6 and had an osmolality of 205^
220 mosmol/ml.
2.5. Cyclic AMP assay
Adenosine 3P,5P-monophosphate (cAMP) was ex-
tracted from the culture supernatants and quanti-
tated by a radiometric protein kinase-binding assay
described previously [12] or supernatants were as-
sayed with a radiometric cAMP binding assay or
an ELISA (Biomedical Technologies, Stoughton,
MA).
2.6. Reaction of PGE2 with imidazole
Structural analysis of PGE2^imidazole by mass
spectroscopy and NMR was facilitated by adding
U-[15N]imidazole to reaction mixtures, which were
incubated at 37‡C for various periods of time up to
24 h. Some reactions were performed using 2.5 WCi
of [5,6,8,11,12,14,15-3H]PGE2 (Amersham Radiola-
beled Chemicals, St. Louis, MO) in lieu of PGE2.
Reaction mixtures were prepared by combining
5 mM PGE2 (Sigma) with 58 mM imidazole or U-
[15N]imidazole. In order to maintain the pH at 7.4,
reaction mixtures contained concentrated (3.3U)
PBS (457 mM NaCl, 9 mM KCl, 4 mM
CaCl2c2H2O, 1.6 mM Mg2Clc6H2O, 27 mM
Na2HPO4, and 4.9 mM KH2PO4). None of the
PBS components was essential for the reaction, since
adduct formation occurred at 37‡C when the pH of
the aqueous solution was manually adjusted to neu-
tral pH with 0.01 N NaOH and the 24-h crude re-
action mixtures were analyzed by mass spectrometry.
2.7. Reverse-phase chromatography
Novel covalent adducts of PGE2 and L-histidine/
imidazole were isolated by reverse-phase chromatog-
raphy on a C-18 (Serva, Paramus, NJ) column
(4.6U250 mm) equilibrated with 26% acetonitrile in
0.1% TFA and £owing at 1.5 ml/min. Covalent ad-
ducts of PGE2 and L-histidine (or imidazole) were
detected in the column eluate at 190 nm, and selected
fractions (1.5 ml) were dried under vacuum. The mo-
lecular structures of the newly formed derivatives
were characterized by MS and NMR spectroscopy.
2.8. NMR spectroscopy
HPLC puri¢ed samples were pooled and dissolved
in 750-Wl of 100% D2O (Cambridge Isotopes) and
analyzed at 20‡C. Spectral assignment of all hydro-
gens of the PGE2^imidazole-adduct was a¡orded by
2D-autocorrelated (COSY) and 2D-totally correlated
(TOCSY; 80 ms mixing time) spectroscopy [13^15].
The position of covalent attachment of imidazole to
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PGE2 was determined by 15N^1H inverse detected
2D-heteronuclear multiple bond correlated spectros-
copy (HMBC2, 90 ms mixing time). All spectra were
collected on a Varian Unity-Plus 600 MHz spectrom-
eter with external reference to HDO (4.70 ppm).
2.9. Mass spectrometry
Positive ion fast atom bombardment mass spec-
trometry (FAB-MS) was performed on a VG Ana-
lytical ZAB-2SE high-¢eld mass spectrometer. A ce-
sium ion gun was used for bombardment of the
sample, which was analyzed in a matrix of glycerol/
thioglycerol (1:1; v/v). Electrospray ionization-MS
was performed with a VG Bio-Q (Quattro II up-
grade) quadrupole mass spectrometer. Samples were
infused in a solvent of acetonitrile/water (1:1; v/v),
containing 0.1% tri£uoroacetic acid at a £ow rate of
10 Wl/min. Daughter ion spectra were generated from
the singly charged parent ions using collisionally ac-
tivated dissociation with argon as the collision gas.
Methyl esteri¢cation was performed using a re-
agent of either methanol/HCl (3:1, v/v) or d3 meth-
anol/HCl (3:1, v/v). After adding the reagent to
lyophilized aliquots of the sample, the reaction was
allowed to proceed at room temperature for 10 min
and ¢nally dried under nitrogen. Acetylation was
performed on lyophilized aliquots of the sample us-
ing a reagent consisting of tri£uoroacetic anhydride/
acetic acid (2:1, v/v). After mixing, the reaction was
allowed to proceed at room temperature for 10 min
and ¢nally dried under nitrogen.
3. Results
3.1. L-Histidine reduces £uid accumulation in mouse
intestinal loops challenged with cholera toxin
Fig. 1 summarizes the £uid accumulation re-
sponses of control mice versus L-histidine-dosed
mice challenged with CT. In this experiment, various
doses of L-histidine were given to the mice during the
6-h observation period by luminal injections of 100
Wl of 175, 44, or 11 mM L-histidine at the time of
challenge followed by three 100-Wl intraperitoneal in-
jections of 175, 44, or 11 mM L-histidine at 0, 2, and
4 h. The results indicate that as the dose of L-histi-
dine was increased, the amount of £uid accumulation
decreased; however, statistical signi¢cance (P6 0.05)
was observed only at the highest dose of L-histidine
tested (14.8 mg).
3.2. E¡ect of L-histidine on PGE2-induced sodium
transport
One possible mechanism by which L-histidine
might reduce CT-induced £uid accumulation in
mouse intestinal loops could be the capacity of L-
histidine to chemically react with PGE2 thereby re-
ducing its biological activity. In vitro, L-histidine re-
duced both basal and PGE2-induced sodium trans-
port in X. laevis epidermis mounted in a modi¢ed
Fig. 1. Inhibitory e¡ect of histidine on £uid accumulation in
mouse intestinal loops challenged with CT (1 Wg) compared to
control mice. Mice were given 100-Wl injections of L-histidine
(175, 44, or 11 mM) by the luminal and intraperitoneal routes
at the time of challenge. Intraperitoneal injections of L-histidine
were repeated at 2 and 4 h after challenge, and the experiment
was terminated after 6 h. Since the mice received four injec-
tions, the total dosage of L-histidine per mouse was 14.8, 3.7,
and 0.93 mg (592, 148, and 39.7 mg/kg). The vertical bars indi-
cate one standard error above and below the arithmetic means.
The asterisk indicates a signi¢cant di¡erence (P6 0.05) as deter-
mined by Dunnett’s Multiple Group Comparison test. The
number of mice per group is indicated above each bar.
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Ussing chamber (Fig. 2). PGE2 (1 WM) increased the
steady-state Na-dependent current (Isc) by 14% (the
maximum PGE2-induced change in Isc was 18 þ 3%,
n = 5, P6 0.01), and 1 WM PGE2 plus 10 mM L-his-
tidine decreased Isc to 30 þ 9% of control (n = 5,
P6 0.025). These data suggested an interaction be-
tween PGE2 and L-histidine that might diminish
PGE2’s stimulatory e¡ect on ion transport.
3.3. Isolation of PGE2^imidazole/^histidine adducts
Incubation of PGE2 and L-histidine or imidazole
together under nitrogen in vitro (pH 7.4, 37‡C, 24 h)
resulted in the formation of novel PGE2^histidine or
PGE2^imidazole covalent adducts. These novel ad-
ducts were isolated by C-18 reverse chromatography
as illustrated for PGE2^imidazole covalent adducts
(Fig. 3A), and two peaks (I and II) of absorbance
Fig. 3. (A) C-18 reverse-phase separation of PGE2 and adducts
of PGE2 and L-histidine. The chromatogram was derived with a
C-18 reverse-phase column eluted with 26% acetonitrile in 0.1%
TFA. Imidazole eluted in the void volume of the column be-
cause of its hydrophilicity. In contrast, PGE2 eluted at 21 min,
while PGA2 and PGB2 would elute about 44 and 46 min, re-
spectively. Two new peaks appeared at approximately 10 and
12 min when reaction mixtures of PGE2 and imidazole, incu-
bated at 37‡C and pH 7.0 for 24 h, were chromatographed. L-
Histidine reaction mixtures (37‡C, pH 7.0, 24 h) yielded a simi-
lar pattern except that the PGE2^histidine peaks eluted at
8 and 9 min. (B) C-18 reverse-phase chromatography of
[3H]PGE2 and imidazole. The chromatogram was derived on
the same column and with the same conditions as in A. A sin-
gle radioactive peak, identical to peak II in A, was observed.
Rechromatography of either peak I or II of PGE2-imidazole
from A eluted as a single peak that coincided with the elution
of [3H]PGE2^imidazole.
Fig. 2. Normalized values of Isc in Ussing chambers. In control,
the tissue was bathed on both sides by NaCl solution. In
PGE2, 1 WM PGE2 was added to the basolateral solution,
which stimulated Na transport and increased the steady-state
Isc by 14% (the maximum PGE2-induced change in Isc was
18 þ 3%, P6 0.01). In PGE2+HIS, a 1 WM PGE2+10 mM L-his-
tidine solution was incubated at 37‡C for 30 min and then
added to the basolateral side. The Isc decreased to 30 þ 9% of
control. The di¡erence in Isc between PGE2 and PGE2+HIS
was 78 þ 21% (P6 0.025).
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(190 nm) were observed. Rechromatography of the
dried fractions from peaks I and II, containing the
PGE2^imidazole adduct, eluted as a single peak com-
parable to peak II of Fig. 3A (data not shown).
Chromatography of reaction mixtures containing
[3H]PGE2 and imidazole (Fig. 3B), containing mini-
mal phosphate bu¡er, also yielded a single peak that
coincided with peak II (Fig. 3A). A virtually identical
chromatography pro¢le was observed for the PGE2^
histidine covalent adducts, except that the two
PGE2^histidine peaks eluted at slightly earlier times
(8 and 9 min) (data not shown).
Mass spectrometry revealed the molecular mass of
the two HPLC peaks containing PGE2^histidine to
be 489 Da, while the molecular mass of each PGE2^
imidazole peak was 403 Da. In a control experiment,
the low pH of the HPLC bu¡ers was not required for
adduct formation, since mass spectroscopic analysis
of crude mixtures of PGE2 and imidazole (37‡C, pH
7.0, 24 h), without puri¢cation, revealed the presence
of adducts (data not shown). Likewise, we observed
that imidazole reacted with both PGA2 and PGB2,
which are similar in structure to PGE2 but lack an ^
OH group on carbon #11 (data not shown). The
masses of the resulting PGA2^imidazole and PGB2^
imidazole adducts by ESI-MS were the same as that
of the PGE2^imidazole covalent adduct (403 Da).
Fig. 5. PGE2^imidazole adduct reduces CT-induced £uid accu-
mulation in murine intestinal loops. PGE2^imidazole adduct
was instilled into ligated intestinal loops at the time of chal-
lenge with CT (1 Wg/loop). The amount of puri¢ed PGE2^imi-
dazole injected into each loop is indicated on the abscissa. (A)
The mice were necropsied after a standard 6-h incubation peri-
od, and £uid accumulation was measured. The vertical bars in-
dicate one standard error above and below the arithmetic
means derived from 5^8 mice per group. The asterisk indicates
a signi¢cant di¡erence (P6 0.05) as determined by Dunnett’s
Multiple Group Comparison test. (B) Cyclic AMP levels in the
intestinal £uids and PBS lavages of negative loops from the
mice in A were assayed by a cAMP ELISA. The vertical bars
indicate one standard error above and below the arithmetic
means derived from 5^8 mice per group.
Fig. 4. Inhibition of CT-induced cAMP formation in CHO cells
with puri¢ed PGE2^imidazole covalent adduct. The results
show the e¡ect of puri¢ed PGE2^imidazole adduct, isolated as
in Fig. 6, on cAMP levels in CT-stimulated CHO cells. The
vertical bars represent standard error of the mean of triplicate
samples from a typical experiment assayed in duplicate with a
cAMP ELISA. The asterisk indicates statistical signi¢cance by
Dunnett’s Multiple Group Comparison test (P6 0.05).
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By blocking the pi or tau nitrogens in the imida-
zole ring of L-histidine with a methyl group, we de-
termined which of the two nitrogens in the imidazole
ring of L-histidine reacted with C11 of PGE2. We
prepared and chromatographed mixtures of PGE2
containing either 1-methyl-L-histidine or 3-methyl-L-
histidine (data not shown). Adduct was detected
when 1-methyl-L-histidine was used, because the tau
nitrogen was available for covalent bonding to C11.
In contrast, the tau nitrogen is blocked by the methyl
group in 3-methyl-L-histidine and no adduct was
formed. Thus, the tau nitrogen of L-histidine is essen-
tial for covalent bonding to C11 of PGE2.
3.4. E¡ect of L-histidine/imidazole on CT-induced
cAMP formation
The addition of puri¢ed PGE2^imidazole adduct
to CT-stimulated CHO cell cultures resulted in sig-
ni¢cant inhibition of CT-induced cAMP formation
(P6 0.05) (Fig. 4). A concentration of 0.5 Wg/ml re-
duced cAMP levels by approximately 50% in a 6-h
incubation period. Similarly L-histidine reduced the
capacity of both PGE2 and CT to stimulate cAMP
formation in CHO cells in vitro with a competitive
cAMP-binding radiometric assay (data not shown).
3.5. PGE2^imidazole adduct reduces CT-induced
£uid accumulation
Considering that puri¢ed PGE2^imidazole inhib-
ited cAMP formation in CT-stimulated CHO cells
(Fig. 4), we tested the capacity of this adduct to
block CT-induced £uid accumulation in murine in-
testinal loops. Fig. 5A shows that PGE2^imidazole,
in doses as low as 100 Wg, instilled into the intestinal
lumen signi¢cantly reduced CT-induced £uid accu-
mulation. A dose of 200 Wg completely blocked £uid
loss following CT challenge during the 6-h observa-
tion period. The cAMP levels (Fig. 5B) in the intes-
tinal loop £uids were markedly reduced by PGE2^
imidazole treatment and coincided with the reduction
in £uid accumulation.
Fig. 7. Stability of the PGE2^imidazole adduct. The PGE2^imi-
dazole adduct (peak II) was isolated by C-18 reverse-phase
chromatography as described in Fig. 3A and lyophilized for
storage. Subsequently, 20-Wg aliquots were diluted in water (200
Wg/ml) and incubated at 37‡C and pH 5.5 under N2 for indi-
cated periods of time. Samples were rechromatographed and
the areas beneath each peak were integrated. As the PGE2^imi-
dazole adduct decreased in concentration, a peak of PGA2
emerged, along with a minor peak comparable with PGE2^imi-
dazole peak I (Fig. 3A).
Fig. 6. Formation of PGE2^histidine covalent adducts when
PGE2 (4.7 mM) was mixed with 181 mM histidine. After incu-
bation at 37‡C pH 7.0) under N2 for periods up to 24 h, the
reaction mixtures were separated by chromatography on a C-18
reverse-phase column eluted with 26% acetonitrile and 0.1%
TFA. The area of the PGE2^histidine peak (190 nm) migrating
at 12.5 min was determined for each time period.
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3.6. Rate of PGE2^histidine adduct formation
The rate of adduct formation was determined by
measuring the relative area under the major absor-
bance peak at 190 nm (approximately 10^12 min) by
C-18 reverse-phase chromatography (Fig. 3A). We
determined that the PGE2^histidine adduct was
formed in the greatest amount when the pH of the
reaction mixture was 6.5 or higher (data not shown).
The amount of adduct formed (peak II) between
PGE2 and histidine was related to time of incubation
with a T1/2 equal to approximately 10 h (Fig. 6). The
kinetics of PGE2^imidazole formation was very sim-
ilar to that of PGE2^histidine.
3.7. Stability of PGE2^imidazole adduct
Puri¢ed PGE2^imidazole adduct (peak II) was di-
luted in water (200 Wg/ml) and incubated at 37‡C for
various periods of time under nitrogen, before re-
Fig. 8. (A) Electrospray-MS/MS daughter ion spectrum obtained from the pseudo-molecular ion at m/z 403 for the PGE2^imidazole
adduct. (B) Electrospray-MS/MS daughter ion spectrum obtained from the pseudo-molecular ion at m/z 419 for the methyl esteri¢ed
PGE2^imidazole (15N) adduct.
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chromatography on the C-18 column. The adduct
appeared stable for approximately 12 h, after which
some decrease was evident by 24 h and only 10%
remained within 1 week (Fig. 7). As the adduct de-
graded, a peak of PGA2 (44 min) increased in con-
centration, and the void volume peak containing imi-
dazole became larger. In addition to PGA2, a second
minor peak appeared, which migrated 1^2 min ear-
lier than the PGE2^imidazole peak. The latter peak
was similar to the PGE2^imidazole adduct peak I
(Fig. 3A) observed during primary chromatography
of crude reaction mixtures of PGE2 and imidazole.
Neutralization of the adduct with PBS before chro-
matography promoted the rapid elimination of the
imidazole group from the PGE2^imidazole adduct
with complete conversion within 12^24 h (data not
shown). Fractions containing the adducts progres-
sively deteriorated when stored at 4‡C, but lyophi-
lized preparations of the adducts stored under N2
were stable at 370‡C.
3.8. Mass spectrometry analysis of the
PGE2^imidazole adducts
FAB-MS analyses of the PGE2^imidazole adduct
isolated from either HPLC peak (Fig. 3A, peak I or
peak II) showed an intense (M+H) pseudomolecu-
lar ion at m/z 403. Similar data were obtained with
ESI-MS. The presence of a single imidazole moiety
in the adduct was con¢rmed by analysis of a U-
[15N]imidazole product, which gave an intense pseu-
domolecular ion at m/z 405. The presence of a free
carboxylic acid was indicated by successful esteri¢ca-
tion of the PGE2^imidazole adducts. This was dem-
Fig. 9. 1H NMR spectrum (A), 2D TOCSY spectrum (B) and 2D 15N/1H HMBC spectrum (C) of PGE2^imidazole adduct in D2O at
600 MHz. In C, F1 is the 15N dimension and F2 is the 1H dimension.
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onstrated by the FAB-MS spectrum of the product
which showed a (M+H) pseudomolecular ion at m/z
419 (methanol) and m/z 422 (d3-methanol). Analysis
of the acetylated adduct (U-15N-labeled) by ESI-MS
showed an (M+H) at m/z 489 consistent with reac-
tion of two acetyl groups.
Collisionally-induced dissociation (CID) [16] of the
PGE2^imidazole adduct and a number of derivatives
was also performed. The spectrum obtained for the
PGE2^imidazole adduct is illustrated in Fig. 8A. The
major daughter ions at m/z 69 and 95 can be assigned
to fragmentation of the imidazole moiety and this
was con¢rmed by the corresponding daughter ion
spectra of the U-15N-labeled adduct, which showed
similar intense daughter ions at m/z 71 and 97 (Fig.
8B). The signal at m/z 263, which was retained in the
spectrum of the U-15N-labeled adduct, was consis-
tent with a concerted fragmentation mechanism in-
volving elimination of the imidazole and cleavage at
C15. Elimination of water from the molecular ion
accounted for the signal at m/z 385, whereas the
low intensity ions between m/z 100^200 were consis-
tent with cleavage along the methylene chains. Fig.
8B illustrates the ESI-MS/MS daughter ion spectrum
for the esteri¢ed PGE2^imidazole adduct and lends
support to the ion assignments already given.
3.9. Derivation of the structure of the
PGE2^imidazole adduct by NMR
Speci¢c information about the chemical structure
of PGE2^imidazole was derived from NMR analysis
and fragmentation patterns by mass spectrometry.
The 1D 1H NMR spectrum of the PGE2^imidazole
Fig. 9 (continued).
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adduct (peak II) is shown in Fig. 9A. The assign-
ments of the 1H signals were accomplished through
analysis of the 2D COSY and TOCSY spectra (Fig.
9B). During the course of the 2D NMR spectra ac-
quisition, some degradation of the sample was noted
with several new peaks appearing. The assignments
were straightforward, with cross peaks in the
TOCSY spectra connecting many of the coupled pro-
tons. Thus, TOCSY correlation is seen for H-13
(5.55 ppm) to H-14, H-15 and H-12 (in order of cross
peak appearance; see Scheme 1 and Table 1 for iden-
ti¢cation of protons). H-5 (5.45 ppm) shows correla-
tion to H-7, H-2, H-4, and H-3. H-14 (5.37 ppm) is
correlated to H-13, H-15, and H-12. H-6 (5.32 ppm)
is correlated to H-5, H-7, H-2 and H-4. H-11 (4.84
ppm) shows correlation in the dimension F-2 to H-
10, H-12, H-8 and H-7 (water presaturation obscures
the diagonal peak and correlation in the F1 dimen-
sion). H-15 (4.03 ppm) is correlated to H-13, H-14,
H-15, H-16, H-16P, H-17, and H-17P. H-10 (3.07
ppm) is correlated to H-11, H-12, H-8, and H-7.
Continuing up¢eld, H-12, H-8, H-7, H-2, H-4, and
H-3 show the expected cross peaks. Finally H-19
(1.16 ppm), H-18 (1.08 ppm), and H-20 (0.76 ppm)
show correlation to each other as well as H-15 and
H-16, thus completing the sequential connectivity of
the protons of the prostaglandin adduct. The down-
¢eld imidazole ring protons were assigned through
the COSY and TOCSY spectra, as well as the 15N/
1H HMBC spectrum of the U-15N-labeled imidazole
PGE2^imidazole adduct sample (Fig. 9C). The latter
spectrum correlated the 15N/1H coupled imidazole
nitrogens with the imidazole protons H-2, H-4 and
H-5 as well as two of the prostaglandin protons.
Fig. 9 (continued).
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Thus, N-1 of the imidazole (5.02 ppm) shows corre-
lation to imidazole H-2 (8.81 ppm), H-4 (7.46 ppm),
and H5 (7.62 ppm) as well as prostaglandin protons
H-12 (2.90 ppm) and H-10P (2.79 ppm). Unfortu-
nately, either because of small coupling or partial
signal saturation due to the proximate HDO reso-
nance, only a small, tentatively identi¢ed cross
peak to the H-11 proton was observed. The correla-
tion to both H-10 and H-12 (large three-bond cou-
pling) con¢rms the site of covalent attachment of the
imidazole ring to the prostaglandin framework. In
addition, the only signi¢cant chemical shift perturba-
tions in the adduct relative to those of the free PGE2
is found for H-11 (+0.74 ppm; + values represent
down¢eld shift for the adduct), H-10, 10P (+0. 65
and +0.35 ppm), H-12 (+0.47 ppm), H-8 (+0.27
ppm) and H-14 (300.19 ppm).
4. Discussion
Mouse intestinal loops challenged with CT and
dosed with L-histidine accumulated signi¢cantly less
£uid than those from the corresponding CT-chal-
lenged control mice (Fig. 1). The L-histidine-medi-
ated reduction in £uid accumulation could be ex-
plained on the basis of possible interference with
one or more mediators involved in its mechanism
of action. CT is known to elicit the increased syn-
thesis of cAMP [12] and PGE2 [1^4], as well as the
release of 5-hydroxytryptamine [6], which cause £uid
secretion by signaling the activation of the enteric
nervous system. We demonstrated a chemical reac-
tion between L-histidine and PGE2, but did not ob-
serve any direct e¡ect of L-histidine on cAMP or 5-
hydroxytryptamine, as determined by HPLC separa-
tion of the resulting reaction mixtures. Prostaglan-
dins were a likely target of L-histidine, based on the
reported e¡ects of L-histidine on prostaglandin levels
in other systems [17,18]. L-Histidine is known to di-
minish PGE2 and thromboxane B2 levels in the
Scheme 1. Proposed mechanism for formation of PGE2^imida-
zole adduct.
Table 1
1H NMR assignments for PGE2^Imidazole adduct
Atom no. N (ppm) (chemical shift) Integral/multiplicitya
IMD H2 8.81 1H/s
IMD H4 7.46 1H/s
IMD H5 7.62 1H/s
H2 2.29 2H/t
H3 1.57 2H/m
H4 1.99 2H/br q
H5 5.45 1H/br q
H6 5.32 1H/br q
H7 2.36 2H/br t
H8 2.58 1H/m
H10 3.07 1H/dd
H10P 2.79 1H/br dd
H11 4.84 1H/br q
H12 2.9 1H/br q
H13 5.55 1H/dd
H14 5.37 1H/dd
H15 4.03 1H/br q
H16 1.39 1H/m
H16P 1.29 1H/m
H17 1.16 1.08 2H/m
H18 1.08 2H/m
H19 1.16 2H/m
CH3-20 0.76 3H/br t
as, singlet ; t, triplet; br, broad; q, quartet; dd, doublet of dou-
blets; m, multiplet.
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course of spontaneous murine autoimmune disease
[19]. Further, Carvounis et al. [18] and Burch et al.
[17] showed in toad urinary bladder preparations in
vitro that histidine greatly diminished accumulation
of PGE2 and thromboxane, respectively. Another
amino acid, alanine, has been reported to reduce
the £uid loss in cholera when added to oral rehydra-
tion £uids [20]. Infusion of alanine into the intestinal
lumen is known to activate the sodium pump, which,
in turn, increases sodium absorption by the intestinal
epithelial cells [21].
Generally, we observed that the dose of L-histi-
dine, providing mouse intestinal loops with maxi-
mum protection against CT-induced £uid accumula-
tion, was relatively large (592 mg/kg), even when
treatment was initiated at the same time as toxin
challenge (Fig. 1). The rapid turnover rate of L-his-
tidine could account for the requirement of relatively
large doses. The half-life of L-histidine in humans
was determined to be about 1.7 h [22], while we
recently reported the half life in mice to be about
45 min [10].
L-Histidine’s protective e¡ect against CT-induced
£uid transport (Fig. 1) could be explained by its re-
action with PGE2. In fact, L-histidine reduced PGE2-
stimulated sodium transport (Isc) across Xenopus lae-
vis epidermis (Fig. 2), which is a cAMP-regulated
mechanism. The di¡erence between control and
PG-treated tissues is small, but statistically signi¢-
cant by a ‘t’ pair analysis enabling detection of small
di¡erences. The reason that L-histidine inhibited the
current to a level below the basal one is that endog-
enous prostaglandins contribute to the generation of
cAMP that determines the basal current [23].
C-18 reverse-phase chromatography of reaction
mixtures of PGE2 and imidazole or L-histidine re-
vealed adjacent peaks at about 10^12 min (Fig.
3A). We suspect that peak I is a less stable isomer
of the adduct, because drying of peak I fractions and
rechromatography of the material on the same col-
umn yields only peak II. The masses of the adducts
(isomers) contained in the adjacent peaks were deter-
mined to be 403 Da for PGE2^imidazole and 489
Da, for PGE2^histidine. Further evidence was pro-
vided by the elution of [3H]PGE2^imidazole as a sin-
gle peak (Fig. 3B) similar to peak II (Fig. 3A). The
stability of the puri¢ed PGE2^imidazole adduct
(peak II) was examined by incubation for various
periods of time in water at 37‡C, pH 5.5 (Fig. 7).
The half-life of the puri¢ed PGE2^imidazole adduct
under these conditions was approximately 2.5 days.
As the PGE2^imidazole adduct degraded, the imida-
zole group was eliminated resulting in the appear-
ance of PGA2. The void volume peak contained
the released imidazole, although we noted a small
amount of peak I adduct.
Since L-histidine was demonstrated to react chemi-
cally with PGE2 (Fig. 3), it was reasonable to con-
sider the possibility that L-histidine inhibited the ac-
tion of PGE2 in murine intestinal loops challenged
with CT. In fact, we demonstrated that the puri¢ed
PGE2^imidazole adduct reduced cAMP levels in cul-
ture supernatants of CHO cells stimulated with CT
(Fig. 4). Since CT is known to elicit the formation of
PGE2 in CHO cells [1], we surmised that L-histidine,
as well as the PGE2^imidazole adduct, interfered
with the activity of PGE2 in the CT-treated cells.
We were unable to measure the reduction of PGE2
in vivo or in vitro by PGE2-speci¢c radioimmuno-
assays, since the PGE2^histidine (or imidazole) ad-
duct appeared to react equally well with antibodies
to PGE2 (data not shown). In part, L-histidine could
have served as a PGE2-inactivating compound,
which provided additional support for the role of
PGE2 in CT-induced secretion of water and electro-
lytes in the small intestine. Additionally, the PGE2^
histidine covalent adduct could serve to inhibit the
potential of PGE2 to stimulate adenylate cyclase. In-
deed, puri¢ed PGE2^imidazole adduct inhibited CT-
induced £uid accumulation and reduced cAMP levels
in murine intestinal loops (Fig. 5A and 5B). In this
case, we suspect that the imidazole moiety inactivates
the native stimulatory e¡ect of PGE2 on ion trans-
port, but it is likely the structural similarity of the
PGE2-adduct to PGE2 that enables it to interfere
with the action of CT-induced PGE2 and £uid accu-
mulation. Other PGE2 analogs (e.g., PGA2 and
PGB2) also reduce CT-induced £uid accumulation
in murine intestinal loops with lower potency (data
not shown).
We also tested another potent nucleophile, N-ace-
tyl-L-cysteine (NAC), to determine whether it would
inhibit CT-induced £uid secretion. When injected i.p.
every hour for 6 h in a dose of 238 mM (100 Wl),
NAC (pH 7.0) had no protective e¡ect for mice
against CT-induced £uid secretion in small intestinal
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loops. Injection of a mixture of NAC and CT (with-
out prior adjustment of the pH to 7.0) into the in-
testinal lumen blocked all intestinal £uid accumula-
tion. NAC’s e¡ect on ion transport could have
resulted from the low pH of the NAC solution. We
concluded that NAC could have damaged the CT
protein toxin or decreased the viability of the small
intestinal epithelial cells.
The NMR results established that the imidazole
ring was covalently linked to PGE2 at C11, in e¡ect,
replacing the hydroxyl group at this carbon (Scheme
1). Similar data were derived for PGE2^histidine
(data not shown). Further, using methylated deriva-
tives of L-histidine, we established that it was the tau
nitrogen, which is furthest away from the carbon
chain, that reacted with C11 of PGE2. The most
reasonable explanation for this chemical transforma-
tion is the initial dehydration of PGE2 (possibly gen-
eral acid/base catalysis by the imidazole group) to
yield the alpha, beta-unsaturated ketone (11-deoxy-
v10-PGE2 ; Scheme 1). Facile Michael-addition of the
imidazole to this alpha, beta-unsaturated ketone will
then yield the 11-deoxy-11-imidazolyl-PGE2 (PGA2).
As shown by the pH dependence to the formation of
this adduct, this occurs through the base-form of the
imidazole. In additional experiments essentially as
described in this report, reaction mixtures were pre-
pared with imidazole in which we substituted PGA2
and PGB2 for PGE2. We observed that all three ei-
cosanoids formed covalent adducts with imidazole
and each had precisely the same mass (403 Da).
These results support the sequence of events shown
in Scheme 1.
Prostaglandins are quite reactive species and read-
ily undergo dehydration. Indeed it has been shown
that albumin can catalyze similar dehydration reac-
tions of the related PGD2 prostaglandin [24]. PGE2
also undergoes dehydration [25]. Isomerization of the
double bond is quite common in prostaglandins, and
it is possible that the initial 11-deoxy-v10-PGE2 can
also rearrange to the more fully conjugated PGB2. It
is quite likely that peak I (Fig. 3A) observed in the
HPLC pro¢le is either another stereoisomer of the
11-deoxy-11-imidazolyl-PGE2 product (the stereo-
chemistry at C11 has not been de¢ned) or the 12-
deoxy-12-imidazolyl-PGB2 formed by addition of
imidazole to C12 of the PGB2 (Scheme 2). It is
thus noteworthy that PGB2 forms adducts with imi-
dazole having the same molecular mass as 11-deoxy-
11-imidazoylyl-PGE2 (Scheme 2). Spectra of the
PGB2 adduct (data not shown) establish that the
adduct is similar in structure to the one formed
from PGE2. Thus, this report reinforces the point
that either imidazole-catalyzed dehydration or base
catalysis (or both) could explain the reaction between
PGE2 and imidazole.
It has been previously noted that albumin can co-
valently bind to various prostaglandins such as 15-
keto-13,14-dihydro-PGE2 [26] and that one possible
mechanism is through nucleophilic addition to an
alpha, beta-unsaturated ketone dehydration product
at C11. The detailed NMR structure analysis de-
scribed for 11-deoxy-11-imidazolyl-PGE2 con¢rms
that such a transformation is indeed quite possible.
The ready addition of imidazole, as well as the imi-
dazolyl ring of histidine (vide infra), strongly sug-
gests that histidine may be one of the residues re-
sponsible for the covalent attachment of proteins to
PGE2. This report raises the possibility that prosta-
glandins may covalently modify proteins via the imi-
dazole group of histidine, altering the activity of the
protein or the eicosanoid.
In conclusion, L-histidine, PGE2^imidazole, and
other imidazole derivatives deserve further study as
possible therapeutic agents to protect the intestinal
mucosa from £uid loss evoked by a variety of enteric
microbial pathogens.
Scheme 2. Structures of PGB2 and PGB2^imidazole adduct.
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